Therapeutic antibodies that neutralize all known coronavirus versions have recently been published in an authoritative journal.
The emergence of each version of SARS-CoV-2 threatens the effectiveness of available vaccines and therapeutic antibodies. The Omicron is so different from the others that it has defeated most of those created before its arrival. Scientists hope to develop an antibodies that can neutralize all versions of SARS-CoV-2. Recently presented in a magazine is not the first and not the last, but it has one advantage that makes it worthy of attention.
Antibodies that neutralize all options
SP1-77, as he is called, was obtained from laboratory mice genetically modified to produce humanized antibodies — mice with human fragments. To single out those who react to SARS-CoV-2, scientists put them in contact with the original Uhman strain. Of all the antibodies that responded, only SP1-77 was able to neutralize the Wuhan strain and all other known options, including those of the Omitron family.
What makes SP1-77 so special? Scientists have studied its structure using cryoelectronic microscopy, a method that allows visualization of the antibodies up to the last amino acid. Like most neutral antibodies, SP1-77 connects to RBD.
Also, "," explains Tom Kirhhausen of Boston Children's Hospital.
This research is primarily evidence that mice used by scientists are capable of developing neutralizing humanized antibodies against SARS-CoV-2. Although SP1-77 demonstrates interesting possibilities in vitro, there is no reason to believe that he is a serious candidate for the role of a new therapeutic antibodies useful for Covid-19 treatment.